Theralizumab - TheraMAB LLC

Drug Profile

Theralizumab - TheraMAB LLC

Alternative Names: TAB-08; TABO8

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TheraMAB
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Phase I/II Plaque psoriasis
  • Phase I Solid tumours
  • No development reported Chronic lymphocytic leukaemia; Rheumatoid arthritis

Most Recent Events

  • 21 May 2018 Theramab LLC terminates a phase II trial in Systemic lupus erythematosus in Russia due to administrative reasons (IV) (NCT02711813)
  • 08 Feb 2017 Phase-I clinical trials in Solid tumours (Metastatic disease, Inoperable/Unresectable, Late-stage disease) in Russia (IV) (NCT03006029)
  • 26 Dec 2016 TheraMAB plans a phase Ib trial for Solid tumours (Metastatic disease, Inoperable/Unresectable, Late-stage disease) in Russia (NCT03006029)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top